Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 500 Unicorn Park Dr WOBURN MA 01801-3377 |
Tel: | 1-339-9702843 |
Website: | https://www.replimune.com |
IR: | See website |
Key People | ||
Philip Astley-Sparke Executive Chairman of the Board | Sushil Patel Chief Executive Officer, Director | Emily Luisa Hill Chief Financial Officer |
Colin Love Chief Operating Officer | Andrew Schwendenman Chief Accounting Officer, Treasurer | Paul Bullock Chief Manufacturing Officer |
Christopher Sarchi Chief Commercial Officer | Konstantinos Xynos Chief Medical Officer |
Business Overview |
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors. |
Financial Overview |
For the nine months ended 31 December 2023, Replimune Group Inc revenues was not reported. Net loss increased 29% to $160.7M. Higher net loss reflects Research and development increase of 50% to $118.4M (expense), General and administrative - Balancing v increase of 33% to $28.8M (expense), Stock-based Compensation in R&D increase of 49% to $11.5M (expense). |
Employees: | 284 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$224.08M as of Dec 31, 2023 |
Net annual income (TTM): | -$209.96M as of Dec 31, 2023 |
Free cash flow (TTM): | -$176.27M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 61,387,786 as of Feb 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |